Skip to content


Registration and Welcome Coffee




Chair’s Opening Remarks



Alexey Lugovskoy
Chief Development Officer
Morphic Therapeutics


Keynote Panel Sessions


Panel: One Vision for the Future of Fibrosis

  • Understand the commonalities between varying fibrotic conditions to better prevent and reduce inflammation
  • Develop a systematic approach to target fibrosis across organs
  • Share data to learn from previous failures and streamline the drug development process
  • Decide whether treatments should be targeting fibrosis as a disease itself or as a response to the disease within that organ



Ganesh Raghu
Professor Medicine in the Division of Pulmonary and Critical Care Medicine
University of Washington


Matthew Breyer
Distinguished Scientist CVM

Alexey Lugovskoy
Chief Development Officer Morphic
Morphic Therapeutics

Lisa Hazelwood
Principal Scientist Liver Disease and
Fibrosis Discovery


Panel: The Trials and Tribulations of Animal Models

  • Decide whether animal models are necessary or whether they can be bypassed
  • Weigh the relevancy of precision-cut organ slices against the longevity of animal models
  • Consider testing multiple animal models for a smoother transition to clinical trial



Alexey Lugovskoy
Chief Development Officer Morphic
Morphic Therapeutics


John Atkinson
Senior Research Scientist Tissue Remodelling

Lee Borthwick
Fibrosis Biology Lecturer and Chief Operating Officer FibroFind
Newcastle University

Masha Poyurovsky
Vice President Discover Biology
Kadmon Corporation LLC

Glenn Rosen
Senior Vice President Preclinical Translational Sciences Small Molecule
Coherus Biosciences


Speed Networking

Establish meaningful business connections at a rapid rate. Efficiency at its finest.



Morning Networking Break 


Research and Discovery Sessions: Novel Targets, Molecules and Pathways


Case Study: Novel Two Pronged Target Approach

  • Develop unique molecules that attack two targets simultaneously to stop the progression of fibrosis across the body
  • Ensure secondary targets are relevant and do not enhance toxicity of treatment


Mehran Moghaddam
Chief Executive Officer
OROX Biosciences



Case Study: Therapeutics for Chronic Fibrotic Diseases

  • The next generation of Galectin-3 inhibitors: from R&D through to
    phase III clinical trials
  • Discovery of functional allosteric inhibitors


Eliezer Zomer Ph.D.
Vice President
Drug Discovery and
Galectin Therapeutics



Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive in Vitro Models of Fibrosis

  • Introducing a standardized, fully humanized commercial 3D cell culture platform for fibrosis research
  • Describing the extracellular matrix (ECM) composition of the substrates that recapitulates the human disease environment in vitro
  • Discussing how this platform can reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process


Dr John O’Neill
Chief Scientific



Case Study: Therapeutic Integrin Inhibition

  • Selective integrin inhibitors block TGF-B activation in a cell and tissue specific manner for the treatment of NASH and IPF
  • PK and PD evaluation of dual αvβ6/αvβ1 inhibitors in humans and primates

Scott Turner
Vice President
Translational Sciences
Pliant Therapeutics



Case Study: Galectin-3 as a Potential Treatment Target

  • Identify patients with galectin-3 mediated fibrogenesis by plasma galectin-3 levels
  • Using the galectin-3 carbohydrate recognition domain as an on-off switch for treatment
  • The promise of galectin-3 inhibition in cardiac and other conditions

Pieter Muntendam
Chief Executive
Officer and Founder
G3 Pharmaceuticals



Building a platform of evidence that will lead to clinical and partnering success in fibrotic disease

  • A view of the future clinical landscape in fibrotic disease – exemplified by IPF and NASH, and the ability of currently available assays to address this
  • The opportunity to improve translation via the use of biomarkers
  • Data sets required by industry partners, VCs, PIs and regulators

Darcey Black PhD
Co-founder and
Director, Translational

Simon Cruwys PhD
Co-founder and Director,


Case Study: Selective ROCK-2 Inhibitor Programme

  • ROCK2 is a kinase central to the signalling processes involved in aberrant wound healing and fibrosis
  • ROCK2 is upregulated in acute and chronic inflammation
  • Inhibition of ROCK2 reduces the pro-fibrotic and pro-inflammatory response disease relevant in vitro and in vivo models.

Emily Offer
Principal Scientist
and Team Leader
Redx Immunology



Q&A Panel: Novel Targets, Molecules and Pathways


Lunch Seminar

Maximize productivity by pairing food with food-for-thought at the optional lunchtime seminar.



Lunch Networking Break


Preclinical Sessions: Translating Biology from Animal to Patient


Case Study: Successful Clinical Trials Start with Carefully
Curated Animal Models

  • Specify readouts based on the biology of the target to reflect the chosen mechanism of action
  • Adopt a poly-pharmacy approach for increased effectiveness
  • Move away from inbred strains in animal models and diversify environment and age ranges

John Atkinson
Senior Research
Scientist Tissue



Case Study: Next Generation In Vitro Models

  • Ensure a smoother transition to clinical trial with precision cut slice
    technology that mimics the function of the organ
  • Recreate the organ culture by replicating the biology and cells that would be found in a person
  • Stimulate the culture with a cause relevant to the chosen clinical disease for authentic progression of fibrosis
  • Use of precision cut slices for the modelling of fibrosis

Lee Borthwick
Fibrosis Biology
Lecturer and Chief
Operating Officer
Newcastle University



Afternoon Networking Break

Preclinical Sessions: Translating Biology from Animal to Patient


Case Study: Defining “Activated” Fibroblasts using Single Cell Sequencing

  • Understand the characteristics of the underlying fibroblast cell population beyond the current recognition as the central mediators of extra-cellar matrix deposition in IPF
  • Use of an unbiased single cell RNA-sequencing analysis of a bleomycin-induced pulmonary fibrosis model to characterize molecular responses to fibrotic injury at the single cell level
  • Analysis of gene expression as analyzed by 3 complementary techniques which together generated a 49-gene signature that defined an activated subpopulation of fibroblasts

Scott Macdonnell
Senior Staff Scientist



Case Study: Use of Technology in the Development of TG2 Inhibitory Therapeutics

  • Development of a glomerular sclerosis organoid model
  • Responses in organoid models which recapitulate rodent in vivo data
  • Creation of CKD primate models for antibody therapies
  • Use of surrogate biomarkers for in vivo studies

Tim Johnson
Director Immunology
Therapeutic Area



Q&A Panel: Translating Biology from Animal to Patient


Speed Learning

Roundtable discussions like you’ve never seen them before.
Uncover the story behind four fibrotic therapeutic developments in one quick-fire session. Each table will be hosted by leading specialist who will share the secrets of their most high-impact strategy; you then get the opportunity to question the host before moving on to your next table.


Poster Session and Drinks Reception

Constructive conversations over cocktails and canapés to the backdrop of posters.